Allergy Therapeutics plc has announced an extension of its block admission, with an application made to the London Stock Exchange for the admission of 5,000,000 ordinary shares of 0.1 pence each in the company. These shares may be issued as a result of the exercise of share options under Allergy Therapeutics' 2013 Long Term Incentive Plan. The admission is expected to become effective on October 5, 2023. The total Block Listing will consist of 12,013,147 Ordinary Shares after this increase. The newly issued shares will rank pari passu with the existing ordinary shares of the company.

In addition, Allergy Therapeutics has provided a block listing interim review, stating that the balance of unallotted securities under the Allergy Therapeutics plc 2013 Long Term Incentive Plan is 7,013,772 ordinary shares. This balance has been updated to account for 105,625 ordinary shares that were issued during the previous review period. No increase in the block scheme has been applied for, and no securities have been issued or allotted under the scheme during the period.

Allergy Therapeutics is a company that specializes in allergy immunotherapy.